NPM1-mutated AML is driven by aberrant HOX/MEIS1 expression, whose mechanistic basis remained unresolved for years. Recent paradigm-shifting studies show that mutant NPM1 organizes phase-separated nuclear condensates that concentrate transcriptional regulators at active chromatin, directly sustaining the pathogenic HOX/MEIS1 transcriptional program. This framework explains the activity of Menin-KMT2A inhibitors, recently approved by the FDA, in this AML subtype and positions disruption of these assemblies as a precision strategy to eliminate oncogenic transcription.
Building similarity graph...
Analyzing shared references across papers
Loading...
Hannah J. Uckelmann
Jayant Yadunath Gadrey
Lorenzo Brunetti
Blood
Goethe University Frankfurt
Tufts Medical Center
Marche Polytechnic University
Building similarity graph...
Analyzing shared references across papers
Loading...
Uckelmann et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d896046c1944d70ce072c3 — DOI: https://doi.org/10.1182/blood.2025031880